Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2026-02-26 Earnings Release
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
Earnings Release 2025
Earnings Release Classification · 95% confidence The document is a 'Bokslutskommuniké' (Year-End Report) for Egetis Therapeutics for the period January-December 2025. It contains detailed financial statements, management commentary on business performance, clinical trial updates, and future outlooks. It is a comprehensive financial report covering a full fiscal year, which aligns with the definition of an Annual Report (10-K equivalent in this context). FY 2025
2026-02-26 Swedish
Audit Report / Information 2025
Audit Report / Information Classification · 95% confidence The document is titled 'Year End report January-December 2025' and contains comprehensive financial statements, management commentary, operational highlights, and outlook for the full fiscal year. It is a formal, detailed report (over 70,000 characters) rather than a short announcement or press release. It fits the definition of an Interim/Quarterly Report (IR) as it covers the full-year period and provides the detailed financial breakdown required for such filings. FY 2025
2026-02-26 English
Egetis slutför rullande ansökan om marknadsgodkännande (NDA) i USA för Emcitate® (tiratricol) för behandling av MCT8-brist
Regulatory Filings Classification · 95% confidence The document is a press release from Egetis Therapeutics announcing the completion of a 'Rolling New Drug Application' (NDA) to the FDA for their drug Emcitate. It details the regulatory status, clinical trial data supporting the application, and future expectations for approval. While it discusses regulatory matters, it is a standard corporate announcement of a filing event rather than a formal regulatory filing itself, and it does not fit into specific categories like 10-K or Earnings Release. It is best classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement regarding regulatory progress.
2026-01-29 Swedish
Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency
Regulatory Filings Classification · 95% confidence The document is a press release from Egetis Therapeutics announcing the completion of a rolling New Drug Application (NDA) submission to the FDA for their drug Emcitate. While it contains detailed information about the drug and clinical trials, it is a corporate announcement regarding a regulatory milestone. According to the 'Menu vs Meal' rule, this is a regulatory announcement rather than a formal regulatory filing or a comprehensive report. It fits best under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement regarding regulatory progress.
2026-01-29 English
Ändring av antalet stamaktier och röster i Egetis Therapeutics
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement regarding a change in the number of shares and voting rights in Egetis Therapeutics AB. It details the conversion of warrants into common shares, resulting in a change in the share structure. This type of corporate disclosure regarding capital structure changes falls under the 'Share Issue/Capital Change' category.
2025-12-30 Swedish
Change in the number of ordinary shares and votes in Egetis Therapeutics
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement regarding a change in the number of ordinary shares and votes in Egetis Therapeutics due to the exercise of options. This type of disclosure is a standard regulatory requirement for listed companies to report changes in share capital and voting rights. It fits the definition of 'Share Issue/Capital Change' (SHA) as it details the specific increase/decrease in share classes and total voting power.
2025-12-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.